Wednesday, October 16, 2013

Boston Therapeutics, Inc. (BTHE) to Present at Livingston Securities Advanced and Nano Life Sciences Summit

Boston Therapeutics today announces it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston Therapeutics, Kenneth A. Tassey, Jr., on October 17, 2013, in New York City.

Mr. Tassey, Jr. will cover Boston Therapeutics’ product pipeline, including PAZ320. Other topics of discussion to be covered during the presentation include the company’s product to reduce post-meal glucose elevation as well as other corporate developments. The presentation will be available on Boston Therapeutics’ website: http://ir.stockpr.com/bostonti/overview.

Headquartered in Manchester, NH, Boston Therapeutics develops drugs that address diabetes using complex carbohydrate chemistry. Specifically the company is focused on development and commercialization of therapeutic molecules that address Type 2 diabetes. The company’s initial product pipeline consists of:

PAZ320, a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.
IPOXYN™, a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN™ is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
OXYFEX™, a product that can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.

The company is backed by a highly experienced and insightful management and scientific advisory team that has extensive expertise in complex carbohydrate chemistry, regulatory, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Its executive management team has more than 100 years of combined experience.

For more information, visit www.bostonti.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html